Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.82 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Pyrrolidone SCHEMBL27827832 | 1.00 | — | — | |
| 2-Pyrrolidone SCHEMBL2389 | 1.00 | — | — | |
| 2-Pyrrolidone SCHEMBL9304498 | 1.00 | OR51E2 (1.00) | OR51E2CRBNFKBP5GAAKDM4E | |
| 2-Pyrrolidone SCHEMBL4299593 | 1.00 | — | — | |
| 2-Pyrrolidone SCHEMBL3453306 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL5274639 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL511486 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL11328078 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL21858973 | 0.97 | — | — | |
| 2-Pyrrolidone SCHEMBL9510 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204062-A1 | PROCESS FOR THE PREPARATION OF REGORAFENIB AND ITS CRYSTALLINE FORMS | SHILPA MEDICARE LIMITED (IN) | 2017-07-20 | — | — | US | claimed |
| EP-1131062-B1 | INJECTABLE PROPOFOL FORMULATIONS | VETERINARY RES ASSOCIATES INC (US) | 2005-01-26 | — | — | EP | claimed |
| JP-2160083-A | — | — | None | — | — | JP | disclosed |
| WO-2024034957-A1 | ELECTROCHROMIC ELEMENT AND WINDOW DEVICE COMPRISING SAME | 에스케이씨 주식회사 | 2024-02-15 | — | — | WO | disclosed |
| WO-2021095482-A1 | METHOD FOR PRODUCING POLYAMIDE, AND POLYAMIDE | 株式会社クレハ | 2021-05-20 | — | — | WO | disclosed |
| CN-109971340-A | A kind of antistatic antirust covers the preparation method of iron film | 常州市贝特织造有限公司 | 2019-07-05 | — | — | CN | disclosed |
| US-9937139-B2 | β-substituted γ-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170246135-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9682921-B2 | β-substituted γ-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3102194-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | Quadriga Biosciences, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160289168-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| WO-1999055505-A1 | DIFFUSABLE ANTISAPSTAIN METHOD AND COMPOSITIONS | NEW ZEALAND FOREST RESEARCH INSTITUTE LIMITED (NZ) | 1999-11-04 | — | — | WO | disclosed |
| CN-1232389-A | Patch preparation | SAITAMA DAIICHI SEIYAKU K K (JP) | 1999-10-20 | — | — | CN | disclosed |
| US-5753373-A | SUBSTRATE COATED WITH INORGANIC METAL OXIDE PARTICLES, NONIONIC SURFACTANTS; SURGICAL FACE, EYE SHIELDS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| CN-1163900-A | Preparation of water-soluble copolymers of at least one water-soluble N-vinyllactam and at least one hydrophobic comonomer | BASF AG (DE) | 1997-11-05 | — | — | CN | disclosed |
| EP-0500625-A1 | COMPOSITION FOR CLEANING AN INTERNAL COMBUSTION ENGINE | PETRO CHEMICAL PRODUCTS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
| EP-0484952-A1 | Meltblown hydrophilic web made from copolymer of an amine-ended polyethylene oxide and a polyamide | FIBERWEB NORTH AMERICA, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1991007578-A1 | COMPOSITION FOR CLEANING AN INTERNAL COMBUSTION ENGINE | PETRO CHEMICAL PRODUCTS INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| US-4997454-A | Precipitation | THE UNIVERSITY OF ROCHESTER (US) | 1991-03-05 | — | — | US | disclosed |
| JP-H02160083-A | FORMATION OF COATING FILM | MAZDA MOTOR CORP | 1990-06-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289168-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC3A2, SLC7A1, SLC43A1 | OR51E2 2532/4885CRBN 4115/4885FKBP5 1999/4885 |
| US-20170204062-A1 | PROCESS FOR THE PREPARATION OF REGORAFENIB AND ITS CRYSTALLINE FORMS | BRAF, ALK, NRAS | OR51E2 3520/4885CRBN 486/4885FKBP5 1406/4885 |
| US-20170246135-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC3A2, SLC7A1, SLC43A1 | OR51E2 2532/4885CRBN 4115/4885FKBP5 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.